Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Asthma (Beclometasone (Qvar) - Asthma)

Records returned : 55 (on 29 May 2025 at 11:25:17). Return to search results for ' Asthma '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
1.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Children only - ICS alone not recommended in adults with asthma.

Second line ICS in children (Clenil Modulite is 1st line).

No dose counter.

Prescribe by BRAND

 
Links :
Indication :
Status :
Green
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important
Preferred

Children only - ICS alone not recommended in adults with asthma.

First line ICS in children.

Prescribe by BRAND

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Not licensed in <18 years. ICS alone not recommended in adults with asthma.

Not to be initiated in new patients.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (breath actuated Metered Dose)
Restrictions / Comments:

Important

No dose counter, high carbon footprint.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (breath actuated Metered Dose)
Restrictions / Comments:

Important

No dose counter, high carbon footprint.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Fostair NEXThaler 100/6 - licensed from 18 years of age.

Not licensed for AIR.

Second line in adult asthma requiring MART. (Fobumix Easyhaler (budesonide/formoterol) is the more cost-effective option DPI)

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Fostair NEXThaler 200/6 - High dose ICS/LABA for specialist recommendation only.

Not licensed for COPD.

Prescribe by BRAND.

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Fostair 100/6, 200/6 not licensed in under 18 years. Not licensed for AIR.

Not for initiation in new patients. Proxor device is much less expensive.

Further information is being sought with regard to Proxor / Fostair bioequivalence. To be reviewed in Jul/Aug 2025.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Proxor 100/6 (new device) - licensed for MART in adults - second line. (Fobumix Easyhaler (budesonide/formoterol) is the more cost-effective option DPI)

Not licensed in under 18 years.

Proxor is equivalent to Fostair and is the most cost-effective ICS/formoterol pMDI.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Proxor 200/6 (new device) - higher dose ICS/LABA for specialist recommendation only.

Licensed for MART in adults - second line.

Not licensed in under 18 years. Not licensed for COPD

Proxor is equivalent to Fostair and is the most cost-effective ICS/formoterol pMDI.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Trimbow 87/5/9 and 172/5/9 - specialist recommendation only

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Not for initiation in new patients.

 
Links :
Indication :
Status :
Green
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Children only - ICS alone not recommended in adults with asthma.

DPI licensed in children, cost effective.

Prescribe by BRAND.

Licensed in children.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Children only - ICS alone not recommended in adults with asthma.

Licensed in children. Second line (Easyhaler budesonide device is preferred).

Prescribe by BRAND

 
Links :
Indication :
Status :
Blue
Formulations :
  • Nebules
Restrictions / Comments:

Important

Specialist recommendation following patient initiation and education on nebuliser therapy.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

DuoResp Spiromax 160/4.5 - licensed for AIR and MART from 12 years of age.

Second line. (Fobumix Easyhaler (budesonide/formoterol) is the more cost-effective option DPI)

Prescribe by BRAND.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

DuoResp Spiromax 320/9 - higher dose ICS/LABA for specialist recommendation only.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Fobumix Easyhaler 80/4.5 and 160/4.5 - licensed in children.

Cost-effective choice for AIR and MART.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Fobumix Easyhaler 320/9 - higher dose ICS/LABA for specialist recommendation only.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Symbicort Turbohaler 100/6 and 200/6 - Licensed for AIR and MART.

More costly device so second line option. (Fobumix Easyhaler (budesonide/formoterol) is the more cost-effective option DPI)

Prescribe by BRAND.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Symbicort Turbohaler 400/12 - higher dose ICS/LABA for specialist recommendation only.

Prescribe by BRAND

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Flixotide Accuhaler - specialist paediatric recommendation. 50 and 100mcg strength only.

Children only - ICS alone not recommended in adults with asthma.

Prescribe by BRAND

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Flixotide Evohaler - specialist paediatric recommendation. 50 and 125 mcg strength only.

Children only - ICS alone not recommended in adults with asthma.

Prescribe by BRAND

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Flutiform 50/5 - For children aged 5 to 11 years needing ICS/LABA, unable to use DPI.

Not recommended for use in adults.

Prescribe by BRAND

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Flutiform 125/5 and 250/10 - on request from specialist team only.

Very high carbon footprint.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Salmeterol containing preparations not recommended in asthma guideline.

Increased risk of adrenal suppression in children.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Salmeterol containing preparations not recommended in asthma guideline.

Increased risk of adrenal suppression in children.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Salmeterol containing preparations not recommended in asthma guideline.

Increased risk of adrenal suppression in children.

Not for initiation in new patients

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Seretide Evohaler 50/25 - for children aged 5 to 11 years needing ICS/LABA, unable to use DPI.

Not recommended for use in adults.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Salmeterol containing preparations not recommended in asthma guideline.

Increased risk of adrenal suppression in children.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Relvar Ellipta 92/22 and 184/22 - higher dose ICS LABA for specialist recommendation only.

Once daily formulation.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

 

 
Links :
Indication :
Status :
Blue
Formulations :
  • Nebules
Restrictions / Comments:

Important

Specialist recommendation following patient initiation and education on nebuliser therapy, unless for administration as PSD in practice for acute attack.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Specialist recommendation only.  Used in severe asthma.

Only triple therapy DPI licensed for asthma.

Prescribe by BRAND

 
Links :
Indication :
Status :
Green
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important
Preferred

Cost-effective, low carbon DPI.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Nebules
Restrictions / Comments:

Important

Specialist recommendation following patient initiation and education on nebuliser therapy, unless for administration as PSD in practice for acute attack.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (breath actuated Metered Dose)
Restrictions / Comments:

Important

Second line, as an alternative to Salbutamol Easyhaler, in patients needing a breath actuated inhaler

Second line - for patients needing a breath-actuated device

 
Links :
Indication :
Status :
Green
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

No dose counter. Lower carbon footprint than Ventolin Evohaler.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important
Preferred

Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Green
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important
Preferred

Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.

Prescribe by BRAND

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

No dose counter. Higher carbon footprint than the Salamol MDI.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Serevent Evohaler

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Serevent Accuhaler

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

Alternative low carbon DPI (Easyhaler Salbutamol is the more cost-effective treatment option)

Prescribe by BRAND.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Nebules
Restrictions / Comments:

Important

Specialist recommendation following patient initiation and education on nebuliser therapy

 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Severe acute asthma
 
Links :
Indication :
Status :
Green
Formulations :
  • Soft mist inhaler
Restrictions / Comments:

Important

Only LAMA licensed in asthma.

Prescribe by BRAND.

 
Links :
Indication :
Status :
Green
Formulations :
  • Chewable tablets
  • Sachets (granules)
  • Tablets
Restrictions / Comments:

Important
https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Inhaler (Metered Dose)
Restrictions / Comments:

Important

Symbicort 100/3 - Useful in children and under 18yrs . Useful for patients needing a pMDI licensed for MART.

Prescribe by BRAND

 
Links :
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Specialised commissioned services only.
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Unlicensed use in under 12 years of age.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Modified release tablets
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Inhaler (dry powder)
Restrictions / Comments:

Important

LABA monotherapy no longer recommended for asthma or COPD.

Not to be initiated in new patients.

Not for initiation in new patients.

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important
Place in therapy under review. Therapeutic drug monitoring required. Not recommended for primary care initiation without specialist advice.
 
Links :